RIFTVAX

RiftVax is a biotechnology company focused on the development of a novel vaccine to prevent Rift Valley fever (RVF), a viral zoonosis that affects both humans and livestock. The company's lead candidate is a live-attenuated vaccine designed to provide robust and long-lasting immunity against the Rift Valley fever virus. By targeting this significant public health and economic threat, RiftVax aims to mitigate the impact of outbreaks in endemic regions. The vaccine technology is based on research aimed at creating a safer and more effective alternative to existing veterinary vaccines, with a primary focus on human clinical application. RiftVax is currently advancing its lead program through early-stage clinical trials to establish safety and immunogenicity.